Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL15743058 | 0.94 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL812443 | 0.94 | — | — | |
| SCHEMBL8185227 | 0.94 | — | — | |
| SCHEMBL18483726 | 0.89 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL17324108 | 0.89 | MEN1 (0.40) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL2738489 | 0.88 | MEN1 (0.51) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL4173315 | 0.88 | MEN1 (0.48) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL23691407 | 0.87 | MEN1 (0.45) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL31749262 | 0.87 | MEN1 (0.45) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL3379348 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7518003-B2 | Production process of tetrahydropyran compound and tetrahydropyran compound produced by the production process | SHOWA DENKO K.K. (JP) | 2009-04-14 | — | — | US | claimed |
| US-20080139828-A1 | Reacting 3,4-dihydro-2-alkoxy-2H-pyran with hydrogen in the presence of a catalyst under acidic condition; Grignard reaction solvent or polymer solvent | SHOWA DENKO K.K. (JP) | 2008-06-12 | — | — | US | claimed |
| EP-1828158-A1 | PRODUCTION PROCESS OF TETRAHYDROPYRAN COMPOUND AND TETRAHYDROPYRAN COMPOUND PRODUCED BY THE PRODUCTION PROCESS | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2007-09-05 | — | — | EP | claimed |
| WO-2006062211-A1 | PRODUCTION PROCESS OF TETRAHYDROPYRAN COMPOUND AND TETRAHYDROPYRAN COMPOUND PRODUCED BY THE PRODUCTION PROCESS | SHOWA DENKO K.K. (JP) | 2006-06-15 | — | — | WO | claimed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| US-20230399471-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING COMPOUND AND METHOD FOR PRODUCING SURFACE TREATMENT AGENT | AGC Inc. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230399293-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING COMPOUND AND FLUORINE-CONTAINING COMPOUND | AGC Inc. (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230226002-A1 | RETINAL BIOAVAILBILITY OF SYNTHETIC VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-07-20 | — | — | US | disclosed |
| WO-2023109878-A1 | TRIAZASPIRO LPAR1 ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-30 | — | — | US | disclosed |
| WO-2022256299-A1 | 7-MORPHOLINO-5-(3-PHENYL-1 H-PYRAZOL-1 -YL)-FURO[3,2-B]PYRIDINE DERIVATIVES AND SIMILAR COMPOUNDS AS PIKFYVE KINASE INHIBITORS FOR THE TREATMENT OF E.G. AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Verge Analytics, Inc. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20070042152-A1 | High-capacity optical storage media | CIBA SPECIALTY CHEMICALS CORP. | 2007-02-22 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
| WO-2006062211-A1 | PRODUCTION PROCESS OF TETRAHYDROPYRAN COMPOUND AND TETRAHYDROPYRAN COMPOUND PRODUCED BY THE PRODUCTION PROCESS | SHOWA DENKO K.K. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-6762170-B1 | ANTIINFLAMMATORY AGENTS INHIBIT LEUKOCYTE RECRUITMENT AND ACTIVATION AND ARE AGONISTS OF THE ADENOSINE 2A RECEPTOR; PENDANT ISOXAZOLE; REACTING A 2,6-DIAMINOPURINE WITH A 2-(3-SUBSTITUTED ISOXAZOL-5-YL)TETRAHYDROFURAN-3,4-DIOL | SMITHKLINEBEECHAM CORPORATION | 2004-07-13 | — | — | US | disclosed |
| EP-1051425-B1 | 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LTD (GB) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001014334-A1 | FLUORENONE COMPOUNDS WITH MODIFIED 7-POSITION SUBSTITUENTS FOR TREATING AND PREVENTING BRAIN AND SPINAL INJURY | QUESTCOR PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
| EP-1051425-A2 | 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999038877-A2 | 2-(PURIN-9-yl)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | CNR2, CNR1, OPRM1 | MEN1 4737/4885KMT2A 2110/4885KDM4C 2936/4885 |
| US-20230226002-A1 | RETINAL BIOAVAILBILITY OF SYNTHETIC VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS | ELOVL1, ELOVL3, FFAR2 | MEN1 3848/4885KMT2A 3613/4885KDM4C 3982/4885 |
| US-20080139828-A1 | Reacting 3,4-dihydro-2-alkoxy-2H-pyran with hydrogen in the presence of a catalyst under acidic condition; Grignard reaction solvent or polymer solvent | HPD, ACR, GRHPR | MEN1 3558/4885KMT2A 2893/4885KDM4C 3150/4885 |
| US-20230399293-A1 | METHOD FOR PRODUCING FLUORINE-CONTAINING COMPOUND AND FLUORINE-CONTAINING COMPOUND | AFF1, AFF4, AFF2 | MEN1 739/4885KMT2A 74/4885KDM4C 404/4885 |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | VIP, DNPEP, HM13 | MEN1 1062/4885KMT2A 3453/4885KDM4C 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.